peginterferon alfa-2b
Phase 2Terminated 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Childhood Craniopharyngioma
Conditions
Childhood Craniopharyngioma
Trial Timeline
Apr 1, 2014 → Jan 1, 2019
NCT ID
NCT01964300About peginterferon alfa-2b
peginterferon alfa-2b is a phase 2 stage product being developed by Brain Biotech for Childhood Craniopharyngioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01964300. Target conditions include Childhood Craniopharyngioma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01964300 | Phase 2 | Terminated |
Competing Products
20 competing products in Childhood Craniopharyngioma